AJANTA PHARMA LTD.

CTL Trusteeship Limited, acting as Common Security Trustee, has created a pledge over 26,21,067 equity shares of Ajanta Pharma Limited. This pledge represents 2.10% of the total share capital and is intended to secure the issuance of non-convertible debentures by Lenexis Foodworks Private Limited and Inspira Realty Private Limited. Following this action, CTL Trusteeship's total encumbered shares, including pledged shares, increased from 13.54% to 13.53%. The total pledged shares held by CTL Trusteeship now stand at 92,53,718, representing 7.41% of the total share capital.

Ajanta Pharma Limited has submitted its Sustainability Report for FY 2025-26, prepared with reference to GRI Standards. This voluntary disclosure complements the BRSR submitted with the Annual Report. The report details the company's initiatives and progress on environmental, social, and governance (ESG) matters, emphasizing its commitment to responsible business practices and long-term value creation. It covers environmental stewardship, strong governance, ethical practices, and a people-first culture. The report is available on the company's website.

Aayush Agrawal, a promoter of Ajanta Pharma Limited, has announced the release of pledge on 98,185 equity shares. The reason cited for this action is loan repayment. This disclosure was made on September 28, 2026, in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The shares were released from pledge by Aayush Agrawal, trustee of Aayush Agrawal Trust. This event signifies a reduction in pledged promoter holding, potentially improving the free float of shares.

Ajanta Pharma Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The trading window will be shut from Thursday, October 1, 2026, until 48 hours after the declaration of the financial results for the second quarter and half-year ended September 30, 2026. This measure is standard practice to prevent insider trading during periods when material non-public information might be available.

Aayush Agrawal, a promoter of Ajanta Pharma Limited, has announced the release of a pledge on 17,36,353 equity shares. The reason cited for this release is loan repayment. This disclosure is made in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The shares were released from pledges held by entities including Gabs Investments Pvt Ltd, Aditya Birla Capital Ltd, and Bajaj Finance Ltd. This action indicates a reduction in pledged promoter holdings, potentially improving the free float of shares.

Ajanta Pharma Ltd has announced its participation in two upcoming investor conferences. The first is the Jefferies India Forum on September 16th, 2026, involving a one-on-one meeting in New Delhi. The second is the PL Capital Mid & Small Cap Conference 2026 on September 28th, 2026, to be held in BKC, Mumbai. The company has confirmed that discussions during these meetings will be based solely on publicly available information. The schedule is subject to change.

Aayush Agrawal, trustee for Ajanta Pharma Limited, has disclosed the release of 9,76,000 equity shares and the creation of a pledge on 9,20,000 equity shares. The release of the pledge was due to loan repayment, while the creation of the new pledge serves as additional security. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, on August 27, 2026. This action impacts the promoter's holding and the encumbered portion of shares in Ajanta Pharma.

Ravi Agrawal, a promoter of Ajanta Pharma Limited and trustee of Ravi Agrawal Trust, has reported the release of a pledge on 6,910 equity shares. The disclosure, made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicates the shares were released due to 'Excess Pledge'. The event occurred on August 14, 2026, with the reporting date being August 19, 2026. The shares were originally pledged for business financing with Gabs Investments Pvt Ltd, with Aditya Birla Capital Limited as the lender and Barclays Securities (India) Private Limited as the DP. This action slightly reduces the promoter's encumbered shareholding.

Ravi Agrawal, trustee of Ravi Agrawal Trust and a promoter of Ajanta Pharma Limited, has disclosed the release of pledge on 54,796 equity shares. The disclosure, made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, cites 'Excess Pledge' as the reason for the release. The shares were released from pledges made to lenders including Deutsche Investments India Pvt Ltd., Bajaj Finance Limited, and INFINA FINANCE LIMITED, with Barclays Securities (India) Private Limited acting as the DP. This action reduces the encumbered shares held by Ravi Agrawal Trust.

Ajanta Pharma Ltd has announced its participation in upcoming investor conferences. The company will attend the Nuvama India Conference 2026 in Singapore & Hong Kong from August 11th to 13th, 2026, and the Motilal Annual Global Conference on August 18th, 2026. These meetings will involve one-on-one discussions with analysts and institutional investors. The company has confirmed that discussions will be based solely on previously published information. The schedule is subject to change.